Alectinib for adjuvant treatment of resectable, ALK mutation-positive non-small-cell lung cancer

Published on 04 Jun 2025
Last Updated on 04 Jun 2025

Guidance Recommendations

The Ministry of Health’s Drug Advisory Committee has not recommended alectinib for inclusion on the MOH List of Subsidised Drugs for adjuvant treatment of resectable, anaplastic lymphoma kinase mutation-positive non-small-cell lung cancer. The decision was due to the unacceptable pricing and price-volume agreement proposed by the company.

Clinical indication, subsidy class and MediShield Life claim limit for alectinib are provided in the Annex.

Alectinib for adjuvant treatment of resectable, ALK mutation-positive non-small-cell lung cancer (Published 4 Jun 2025)